ArticleCureus2026
Role of the Transcranial Doppler Bubble Test in the Diagnostic Pathway of a Patent Foramen Ovale in Embolic Stroke of Undetermined Source.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA patent foramen ovale (PFO) is frequently found in embolic stroke of undetermined source (ESUS). The transcranial Doppler (TCD) bubble test allows for the sensitive detection of right-to-left shunt but is still underused in standard diagnostic procedures.
objectiveThis study aimed to evaluate the clinical impact of the TCD bubble test on diagnostic reclassification and secondary prevention strategies in patients with ESUS.
methodsWe conducted a retrospective observational study including ESUS patients admitted to the Department of Neurology, Ibn Rochd University Hospital, a tertiary care neurology center in Casablanca, Morocco, between January 2023 and July 2025. All patients underwent the TCD bubble test. Transesophageal echocardiography (TEE) was performed when clinically indicated. Right-to-left shunt severity was graded according to international consensus criteria. PFO was considered confirmed only when functional evidence on TCD and anatomical confirmation on TEE were concordant. Clinical, imaging, and therapeutic data were analyzed descriptively.
resultsA total of 117 patients met the inclusion criteria (mean age 45.5 ± 12.4 years; 73/117 (62.0%) female). TCD detected a right-to-left shunt in 48/117 patients (41.0%), with a severe shunt or curtain effect observed in 23/117 patients (19.7%). An adequate Valsalva maneuver was achieved in 109/117 examinations (93.2%). TEE was performed in 59/117 patients (50.4%). Initial discordance between TCD and TEE was observed in 13/59 patients (22.0%). Repeat TEE, performed in selected discordant cases, led to diagnostic correction in all re-evaluated patients, increasing final concordance to 54/59 (91.5%). Overall, PFO was confirmed in 39/117 patients (33.3%). In one patient with a severe shunt on TCD and a negative TEE, further evaluation revealed a pulmonary arteriovenous malformation. TCD findings directly influenced clinical management, including antithrombotic strategy selection and referral for percutaneous PFO closure. Percutaneous closure was performed in 22/117 patients (18.8%), including selected individuals aged ≥60 years with high-risk functional and anatomical features.
conclusionsIn patients with ESUS, the TCD bubble test provides valuable clinical information that corrects diagnostic errors and directly influences secondary prevention strategies. By guiding the use and interpretation of TEE and supporting personalized treatment decisions, TCD acts as an effective first-line screening and gatekeeper tool in ESUS diagnostic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.